Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 7/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916456 | 0.93 | FKBP1A (0.38) | FKBP1ARORCCYP2C9LMNAALDH1A1 | |
| SCHEMBL2915001 | 0.93 | FKBP1A (0.38) | FKBP1ARORCCYP2C9LMNAALDH1A1 | |
| SCHEMBL2922625 | 0.93 | FKBP1A (0.38) | FKBP1ARORCCYP2C9LMNAALDH1A1 | |
| SCHEMBL2916459 | 0.93 | FKBP1A (0.38) | FKBP1ARORCCYP2C9LMNAALDH1A1 | |
| SCHEMBL2920169 | 0.93 | NPC1 (0.39) | FKBP1ARORCCYP2C9LMNAALDH1A1 | |
| SCHEMBL5503122 | 0.93 | NPC1 (0.39) | FKBP1ARORCCYP2C9LMNAALDH1A1 | |
| SCHEMBL2919792 | 0.92 | FKBP1A (0.37) | FKBP1ARORCCYP2C9LMNAALDH1A1 | |
| SCHEMBL2913268 | 0.92 | KMT2A (0.37) | FKBP1ARORCCYP2C9LMNAALDH1A1 | |
| SCHEMBL2919069 | 0.92 | RORC (0.36) | FKBP1ARORCCYP2C9LMNAALDH1A1 | |
| SCHEMBL2919684 | 0.92 | RORC (0.36) | FKBP1ARORCCYP2C9LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863803-B1 | SUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1958634-A2 | Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
| EP-1897879-A2 | 2,4,5 substituted piperidines as renin inhibitors | Speedel Experimenta AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| EP-1863803-A2 | SUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103277-A2 | 2 , 4 , 5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGT, AGTR1 | FKBP1A 3930/4885RORC 4757/4885CYP2C9 3835/4885 |
| US-20080171748-A1 | Substituted piperidines | REN, ACE, AGTR2 | FKBP1A 3129/4885RORC 2727/4885CYP2C9 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.